0

Product Usage

THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic.

CJC-1295 DAC 5mg

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed to increase plasma levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). It is derived from the first 29 amino acids of GHRH, similar to Sermorelin and Modified GRF (1-29), but modified for enhanced stability and efficacy.

$50.00

Peptides will arrive in a lyophilized (powder) form for maximum stability

Out of stock

Buy 5 for 5% off
Buy 10 for 10% off
Buy 15 for 15% off

OVERVIEW

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed to increase plasma levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). It is derived from the first 29 amino acids of GHRH, similar to Sermorelin and Modified GRF (1-29), but modified for enhanced stability and efficacy.

The DAC (Drug Affinity Complex) version of CJC-1295 includes an additional lysine linker, allowing it to bind to albumin, significantly extending its half-life. This prolonged activity leads to sustained GH release, reducing the need for frequent dosing compared to non-DAC versions.

Key Benefits of CJC-1295 DAC:

  • Increases GH and IGF-1 levels
  • Enhances protein synthesis and muscle recovery
  • Boosts fat metabolism and supports weight management
  • Improves sleep quality and cognitive function
  • Preserves natural GH pulsatility, reducing side effects

RESEARCH

CJC-1295 and Growth Hormone Release

CJC-1295 binds to GHRH receptors, triggering GH secretion while maintaining the body’s natural pulsatile rhythm. Research findings indicate that:

  • A single dose of CJC-1295 can increase GH levels by 2-10 times.
  • Peak GH secretion occurs around 2 hours post-administration and remains elevated for 6-8 days.
  • Unlike exogenous GH injections, which can suppress natural GH production, CJC-1295 stimulates endogenous GH release, minimizing suppression risks.

Comparison: CJC-1295 vs. CJC-1295 DAC

Feature CJC-1295 (No DAC) CJC-1295 DAC
Half-Life ~30 minutes ~8 days
Dosing Frequency Multiple injections daily Weekly
Mechanism Short-acting GHRH analogue Binds to albumin for sustained GH release

The DAC modification allows CJC-1295 to stay in circulation longer, preventing rapid degradation, and promoting longer-lasting GH stimulation.

Effects on Muscle Growth

Animal studies suggest that CJC-1295 enhances lean body mass through:

  • Increased protein synthesis, supporting muscle hypertrophy and faster recovery.
  • Improved nitrogen retention, aiding in muscle maintenance.
  • Enhanced mitochondrial function, potentially boosting endurance and energy production.

CJC-1295 and Fat Metabolism

CJC-1295 has been linked to fat reduction and improved metabolic function by:

  • Enhancing GH-induced fatty acid oxidation, leading to more efficient fat breakdown.
  • Reducing fat accumulation, particularly visceral and subcutaneous fat.
  • Improving insulin sensitivity, which helps regulate glucose levels and metabolic efficiency.

Clinical studies indicate significant fat loss in subjects using CJC-1295 over 12-24 weeks.

CJC-1295 and Sleep Quality

Research suggests that CJC-1295 may play a role in enhancing sleep cycles, particularly:

  • Increasing deep (slow-wave) sleep, crucial for muscle repair, memory consolidation, and recovery.
  • Modulating cortisol and stress hormones, leading to better relaxation and stress resilience.

These sleep-related benefits contribute to overall well-being, cognitive function, and physical recovery.

CJC-1295 and Anti-Aging Potential

Due to its ability to boost GH and IGF-1 levels, CJC-1295 has been explored for its potential in longevity and regenerative medicine. Benefits may include:

  • Improved bone density, reducing age-related bone loss.
  • Enhanced skin elasticity and collagen production, contributing to youthful skin.
  • Cognitive protection, potentially aiding in neuroprotection and memory retention.

STRUCTURE

  • Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
  • Molecular Weight: 3647.954 g/mol
  • Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-DAC
  • CAS Registry Number: 446262-90-4
  • PubChem Identifier: 91976842

CITATIONS

  1. Ionescu, M., & Frohman, L. A. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J. Clin. Endocrinol. Metab. (2006).
  2. Alba, M. et al. Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in knockout mice. Am. J. Physiol. Endocrinol. Metab. (2006).
  3. Volpe, A. et al. Clinical use of growth hormone-releasing factor for induction of superovulation. Hum. Reprod. (1991).
  4. Jetté, L. et al. hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats.Research Gate (2005).

 

OVERVIEW

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed to increase plasma levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). It is derived from the first 29 amino acids of GHRH, similar to Sermorelin and Modified GRF (1-29), but modified for enhanced stability and efficacy.

The DAC (Drug Affinity Complex) version of CJC-1295 includes an additional lysine linker, allowing it to bind to albumin, significantly extending its half-life. This prolonged activity leads to sustained GH release, reducing the need for frequent dosing compared to non-DAC versions.

Key Benefits of CJC-1295 DAC:

  • Increases GH and IGF-1 levels
  • Enhances protein synthesis and muscle recovery
  • Boosts fat metabolism and supports weight management
  • Improves sleep quality and cognitive function
  • Preserves natural GH pulsatility, reducing side effects

RESEARCH

CJC-1295 and Growth Hormone Release

CJC-1295 binds to GHRH receptors, triggering GH secretion while maintaining the body’s natural pulsatile rhythm. Research findings indicate that:

  • A single dose of CJC-1295 can increase GH levels by 2-10 times.
  • Peak GH secretion occurs around 2 hours post-administration and remains elevated for 6-8 days.
  • Unlike exogenous GH injections, which can suppress natural GH production, CJC-1295 stimulates endogenous GH release, minimizing suppression risks.

Comparison: CJC-1295 vs. CJC-1295 DAC

Feature CJC-1295 (No DAC) CJC-1295 DAC
Half-Life ~30 minutes ~8 days
Dosing Frequency Multiple injections daily Weekly
Mechanism Short-acting GHRH analogue Binds to albumin for sustained GH release

The DAC modification allows CJC-1295 to stay in circulation longer, preventing rapid degradation, and promoting longer-lasting GH stimulation.

Effects on Muscle Growth

Animal studies suggest that CJC-1295 enhances lean body mass through:

  • Increased protein synthesis, supporting muscle hypertrophy and faster recovery.
  • Improved nitrogen retention, aiding in muscle maintenance.
  • Enhanced mitochondrial function, potentially boosting endurance and energy production.

CJC-1295 and Fat Metabolism

CJC-1295 has been linked to fat reduction and improved metabolic function by:

  • Enhancing GH-induced fatty acid oxidation, leading to more efficient fat breakdown.
  • Reducing fat accumulation, particularly visceral and subcutaneous fat.
  • Improving insulin sensitivity, which helps regulate glucose levels and metabolic efficiency.

Clinical studies indicate significant fat loss in subjects using CJC-1295 over 12-24 weeks.

CJC-1295 and Sleep Quality

Research suggests that CJC-1295 may play a role in enhancing sleep cycles, particularly:

  • Increasing deep (slow-wave) sleep, crucial for muscle repair, memory consolidation, and recovery.
  • Modulating cortisol and stress hormones, leading to better relaxation and stress resilience.

These sleep-related benefits contribute to overall well-being, cognitive function, and physical recovery.

CJC-1295 and Anti-Aging Potential

Due to its ability to boost GH and IGF-1 levels, CJC-1295 has been explored for its potential in longevity and regenerative medicine. Benefits may include:

  • Improved bone density, reducing age-related bone loss.
  • Enhanced skin elasticity and collagen production, contributing to youthful skin.
  • Cognitive protection, potentially aiding in neuroprotection and memory retention.

STRUCTURE

  • Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
  • Molecular Weight: 3647.954 g/mol
  • Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-DAC
  • CAS Registry Number: 446262-90-4
  • PubChem Identifier: 91976842

CITATIONS

  1. Ionescu, M., & Frohman, L. A. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J. Clin. Endocrinol. Metab. (2006).
  2. Alba, M. et al. Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in knockout mice. Am. J. Physiol. Endocrinol. Metab. (2006).
  3. Volpe, A. et al. Clinical use of growth hormone-releasing factor for induction of superovulation. Hum. Reprod. (1991).
  4. Jetté, L. et al. hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats.Research Gate (2005).

 

All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind.

The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

Biogenesis Peptides is a chemical supplier. Biogenesis Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Biogenesis Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.